Willbe launches FemGene test, combining hormone and genetic testing to guide personalized HRT interventions.
British female health and longevity company Willbe today launched what it claims is the world’s first platform combining genetics and hormone testing to predict how women experience perimenopause and respond to treatment. The company has introduced a new test called FemGene as it seeks to move perimenopause care away from trial-and-error approaches and toward preventative, individualized medicine.
Willbe is targeting perimenopause as a key inflection point for women’s long-term health. The company claims that treatment has typically relied on symptom management through iterative hormone adjustments, a process that can take years and leave women exposed to preventable risks such as bone loss, cardiometabolic disease and cognitive decline.
“Perimenopause is not just declining hormones – it’s an epigenetic reprogramming event,” said Willbe founder Yulia Mintchin, a biomedical scientist-turned-entrepreneur. “The body says: the way I used to run no longer works.”
Willbe’s platform combines genetic analysis, hormone testing and the prescription of bioidentical hormone therapy to build predictive treatment pathways intended to extend healthspan. The company focuses on how falling estrogen and progesterone levels during perimenopause alter gene expression across multiple biological systems. The degree to which these changes occur, and how disruptive they become, varies widely between women. Willbe’s “hormogenetics” approach addresses why that variability exists by examining inherited genetic differences that shape how hormones are produced, metabolized, cleared and received by target tissues.
“Whether a woman thrives or struggles is written in her genes,” said Mintchin. “As hormones decline, gene expression shifts – driving how she ages, repairs, and restores. That’s why women on the same HRT dose can have completely different outcomes.”
The company’s new FemGene test analyzes more than 350 genetic variants across 125 genes and organizes them into functional clusters linked to sleep and brain resilience, detoxification and inflammatory control, nutrient dependencies, hormone receptor sensitivity and metabolic flexibility. After taking the saliva-based test, each participant receives a report structured across four domains – hormone function, detoxification capacity, longevity-associated pathways and what the company terms “radiance,” a category that includes skin, hair and visible aging markers. The data are then translated into an individualized action plan, which may include targeted bioidentical hormone prescriptions, nutrition strategies, supplementation and ongoing lifestyle coaching. Test packages start at £500, and include a 45 minute consultation with a clinician.
FemGene leverages genetic data to classify women into three broad hormonal archetypes. The “Resilient” archetype reflects genetic profiles associated with efficient hormone clearance, lower inflammatory responses and comparatively mild symptoms. The “Sensitive” archetype reflects heightened receptor sensitivity and vulnerability in neurotransmitter and detoxification pathways, often linked to anxiety, fatigue and pronounced reactions to shifting hormones. The “Silent” archetype captures women who may report few outward symptoms yet show genetic risk patterns associated with internal changes such as bone loss or emerging insulin resistance. The intent of these classifications is to guide the timing and intensity of interventions, particularly for women who might otherwise be overlooked because they do not present with classic symptoms.
“By decoding each woman’s genetic blueprint, we can predict her hormonal journey and deliver targeted solutions from day one,” said Mintchin. “This is the moment women move beyond trial-and-error healthcare into precision longevity medicine.”
